• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    7/9/25 9:03:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    false 0001737927 Canopy Growth Corp 00-0000000 0001737927 2025-07-09 2025-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): July 9, 2025

     

     

    Canopy Growth Corporation

    (Exact name of registrant as specified in its charter)

     

     

    Canada   001-38496   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1 Hershey Drive
    Smiths Falls, Ontario
    K7A 0A8
    (Address of principal executive offices) (Zip Code)

     

    (855) 558-9333

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Common Shares, no par value   CGC   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company    ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Termination of Chief Financial Officer

     

    On July 9, 2025, Canopy Growth Corporation (the “Company”) terminated the employment of its Chief Financial Officer, Judy Hong, effective immediately (the “Separation”). Ms. Hong’s termination was not related to the Company’s financial or operating results or to any disagreements or concerns regarding the Company’s financial or reporting practices. Ms. Hong was terminated “without cause” under the terms of her employment agreement with a wholly owned subsidiary of the Company, dated March 29, 2022 (as amended, the “Hong Employment Agreement”). As previously disclosed, subject to Ms. Hong’s compliance with the terms of the Hong Employment Agreement including Ms. Hong’s entry into a separation, release and waiver of liability, Ms. Hong will be entitled to the payments and benefits provided for by the Hong Employment Agreement following a termination without cause. Ms. Hong will also be entitled to payment of her retention bonus of US$150,000 pursuant to the retention agreement entered into with the Company on August 19, 2024. There are no family relationships between Ms. Hong and any other officer or any of the directors of the Company. There are no transactions in which Ms. Hong has an interest requiring disclosure under Item 404(a) of Regulation S-K.

     

    Appointment of Interim Chief Financial Officer

     

    Effective as of the Separation, the Company appointed its current Vice President, Finance, Thomas Stewart, as the Company’s interim Chief Financial Officer while the Company conducts a search for a permanent Chief Financial Officer.

     

    Thomas Stewart, age 43, has served as the Company’s Vice President, Finance since August 2023, where he is responsible for a wide range of the Company’s finance functions, including external reporting, financial close technical accounting, financial close processes, transactional services, tax, FP&A, commercial finance, and operations finance. Prior to that role, Mr. Stewart served as the Company’s Chief Accounting Officer from April 2019 until August 2023. Prior to joining the Company in April 2019, Mr. Stewart spent over 10 years at Constellation Brands, Inc., where he held a variety of roles within the finance organization, most recently serving as Senior Director, Global Accounting from June 2018 to April 2019. Mr. Stewart started his career at PricewaterhouseCoopers in Rochester, NY and obtained his Bachelor of Science in Accounting from the State University of New York at Geneseo. Mr. Stewart is a Certified Public Accountant in the state of New York and brings a wealth of U.S. GAAP experience to the Company.

     

    There are no arrangements or understandings between Mr. Stewart and any other person pursuant to which he was selected as interim Chief Financial Officer. Mr. Stewart does not have any family relationships with any of the Company’s directors, executive officers, or other person nominated or chosen by the Company to become a director or executive officer. There are no transactions between Mr. Stewart and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

     

    In connection with his service as interim Chief Financial Officer, Mr. Stewart entered into an interim offer letter, dated July 9, 2025 (the “Offer Letter”), pursuant to which Mr. Stewart will receive a monthly stipend of an additional US$7,500 per month in addition to his current base salary until the Company selects a permanent Chief Financial Officer. In addition to the monthly stipend, pursuant to the Offer Letter, Mr. Stewart’s fiscal 2026 short-term annual incentive performance bonus will be calculated at 75% of his base salary and monthly stipend combined and will be prorated based on his time in the interim Chief Financial Officer role.

     

    The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Offer Letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Report”).

     

     

     

     

    Item 7.01Regulation FD Disclosure.

     

    On July 9, 2025, the Company issued a press release titled “Canopy Growth Appoints Tom Stewart as Interim Chief Financial Officer,” a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein solely for purposes of this Item 7.01 disclosure.

     

    The information set forth and incorporated by reference in Item 7.01 of this Report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information set forth and incorporated by reference in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1   Interim Offer Letter, dated July 9, 2025, between Canopy Growth Corporation and Thomas Stewart.
    99.1     Press Release, dated July 9, 2025.
    104     Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    CANOPY GROWTH CORPORATION
      
     By: /s/ Christelle Gedeon
       Christelle Gedeon
       Chief Legal Officer
      
    Date: July 9, 2025

     

     

     

     

    Get the next $CGC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Atkins M Shan was granted 45,680 shares (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    8/14/25 4:15:13 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Atkins M Shan

    3 - Canopy Growth Corp (0001737927) (Issuer)

    8/8/25 4:30:16 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Stewart Thomas Carlton claimed ownership of 73,971 shares (SEC Form 3)

    3 - Canopy Growth Corp (0001737927) (Issuer)

    7/11/25 5:20:17 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    SEC Filings

    View All

    SEC Form DEFA14A filed by Canopy Growth Corporation

    DEFA14A - Canopy Growth Corp (0001737927) (Filer)

    8/15/25 4:15:17 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    8/8/25 7:06:37 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Canopy Growth Corporation

    10-Q - Canopy Growth Corp (0001737927) (Filer)

    8/8/25 6:45:50 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Canopy Growth with a new price target

    Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

    11/2/22 6:11:10 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Canopy Growth from Sell to Hold

    10/26/22 7:36:52 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy USA Appoints New Executive Team to Accelerate Growth Across U.S. Cannabis Market

    New leaders will be responsible for driving portfolio growth, operational improvements, and market expansion BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. cannabis market, today announced the appointment of a new executive team responsible for driving the Company's next phase of expansion. Drawing on extensive industry experience, these leaders will steer Canopy USA forward through a shared vision to elevate the compa

    8/18/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Mailing and Filing of Proxy Materials for Annual General and Special Meeting and Urges All Shareholders to Vote Now

    Voting is important and easy; shareholders are urged to vote today to help the Company avoid incurring additional costs. Canopy Growth shareholders with a 16-digit control number can vote online at http://proxyvote.com, and by phone at 1-800-474-7493. For more information, shareholders should contact Canopy Growth's strategic shareholder advisor and proxy solicitation agent, Laurel Hill Advisory Group, at 1-877-452-7184 (1‑416‑304‑0211 for collect calls outside North America) or by email at [email protected]. Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) announced today that the Company has mailed (or mailed a notice of internet availa

    8/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis Revenue Increased 24% Year-Over-Year

     Canada adult-use cannabis Q1 FY2026 net revenue increased 43% year-over-year, benefiting from increased distribution and strong consumer demand for new products, including Claybourne infused pre-roll joints Company has achieved $17MM of planned $20MM annualized savings target since March 1, 2025; SG&A expenses down 21% year-over-year in Q1 FY2026 compared to Q1 FY2025 Supply chain improvements in international markets expected to increase cannabis supply and consistency in margin accretive European markets in the second half of FY2026 Company expects to launch a new Storz & Bickel vaporizer during the second half of the calendar year Canopy Growth Corporation ("Canopy Growth" or th

    8/8/25 7:00:00 AM ET
    $CGC
    $DRI
    Medicinal Chemicals and Botanical Products
    Health Care
    Restaurants
    Consumer Discretionary

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy USA Appoints New Executive Team to Accelerate Growth Across U.S. Cannabis Market

    New leaders will be responsible for driving portfolio growth, operational improvements, and market expansion BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. cannabis market, today announced the appointment of a new executive team responsible for driving the Company's next phase of expansion. Drawing on extensive industry experience, these leaders will steer Canopy USA forward through a shared vision to elevate the compa

    8/18/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Mailing and Filing of Proxy Materials for Annual General and Special Meeting and Urges All Shareholders to Vote Now

    Voting is important and easy; shareholders are urged to vote today to help the Company avoid incurring additional costs. Canopy Growth shareholders with a 16-digit control number can vote online at http://proxyvote.com, and by phone at 1-800-474-7493. For more information, shareholders should contact Canopy Growth's strategic shareholder advisor and proxy solicitation agent, Laurel Hill Advisory Group, at 1-877-452-7184 (1‑416‑304‑0211 for collect calls outside North America) or by email at [email protected]. Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) announced today that the Company has mailed (or mailed a notice of internet availa

    8/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Appoints Miles Worne as Managing Director of European Markets

    Appointment reinforces Canopy Growth's focus on accelerating growth in Europe and delivering on its Global Medical strategy Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, today announced the appointment of Miles Worne as Managing Director of European Markets, effective August 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731923014/en/Canopy Growth Appoints Miles Worne as Managing Director of European Markets Mr. Worne will be responsible for leading the Company's commercial opera

    7/31/25 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis Revenue Increased 24% Year-Over-Year

     Canada adult-use cannabis Q1 FY2026 net revenue increased 43% year-over-year, benefiting from increased distribution and strong consumer demand for new products, including Claybourne infused pre-roll joints Company has achieved $17MM of planned $20MM annualized savings target since March 1, 2025; SG&A expenses down 21% year-over-year in Q1 FY2026 compared to Q1 FY2025 Supply chain improvements in international markets expected to increase cannabis supply and consistency in margin accretive European markets in the second half of FY2026 Company expects to launch a new Storz & Bickel vaporizer during the second half of the calendar year Canopy Growth Corporation ("Canopy Growth" or th

    8/8/25 7:00:00 AM ET
    $CGC
    $DRI
    Medicinal Chemicals and Botanical Products
    Health Care
    Restaurants
    Consumer Discretionary

    Canopy Growth to Report First Quarter Fiscal 2026 Financial Results on August 8, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the first quarter fiscal year 2026 ended June 30, 2025 before financial markets open on August 8, 2025. Following the release of its first quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, Interim CFO on August 8, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=8135284A-F8CD-45B7-A384-634DE6714986 Replay Information A replay will be accessible by webcast until 11:59 PM ET on November 6, 2025 at:

    7/25/25 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Canada cannabis revenue increased 4% in Q4 FY2025 year-over-year, led by 13% growth in Canada medical cannabis Reduced total debt by $293 million or 49% during FY2025 Refined strategy, focus and organizational structure expected to accelerate growth in global medical cannabis and improve commercial execution in Canada adult-use cannabis Additional cost reduction initiatives identified and initiated in Q4 FY2025 are expected to deliver at least $20 million in annualized savings over the next 12-18 months Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") a

    5/30/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care